Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients (original) (raw)
Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients
Asco Meeting Abstracts, 2014
James Murray
Jennifer Litton
James Murray
John Berry
Michael Papamichail hasn't uploaded this paper.
Let Michael know you want this paper to be uploaded.
Ask for this paper to be uploaded.